A Proof-of Concept Study to Separately Study Talacotuzumab or Daratumumab in Low-Risk Intermediate-1 Risk Myelodysplastic Syndromes (MDS) patients The primary objective of the study is to evaluate the efficacy (transfusion independence [TI]) of talacotuzumab (JNJ-56022473) or daratumumab in transfusion-dependent subjects with low or intermediate...

• Country None
• organs None
• Specialty None

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients with Schizophrenia The primary objective of this study is to evaluate the efficacy of PP3M compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.

• Country None
• organs None
• Specialty None

Etude ATLAS : étude de phase 3 randomisée comparant l’apalutamide et le bicalutamide chez des patients ayant un cancer de la prostate localisé ou localement avancé à haut risque et recevant une radiothérapie en traitement primaire. Les cancers dits « à haut risque de progression » représentent jusqu’à 20% des cancers de prostate localisés. Le traitement de référence est l’association d’une radiothérapie et d’une hormonothérapie,...

• Country France
• organs Prostate
• Specialty Radiothérapie, Hormonothérapie

Safety and Effectiveness of the Coronary Momo Stent This study evaluates the safety and effectiveness of the Momo Cobalt Chromium stent system for the treatment of single de novo lesions in a native coronary artery. The stent is coated with...

• Country None
• organs None
• Specialty None

A blinded-initiation study of medication satisfaction in subjects with schizophrenia treated with paliperidone ER after suboptimal response to oral risperidone The primary objective of this study is to assess the observed change in the Medication Satisfaction Questionnaire (MSQ) score, from baseline to the Week 6 endpoint, when paliperidone ER (6 mg to 12 mg...

• Country None
• organs None
• Specialty None

A Randomized, Multicenter, Open-Label, Study of Alimta® (pemetrexed) plus VELCADE® (bortezomib) or Alimta Alone or VELCADE alone in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy Establish the objective tumor response rate (CR + PR) following treatment with VELCADE plus Alimta or Alimta alone or VELCADE alone in subjects with locally advanced or metastatic NSCLC who have faile...

• Country None
• organs None
• Specialty None

Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues This is a prospective randomized, open-label, phase IV clinical trial to learn the effects, good and/or bad, of discontinuing or continuing nucleos(t)ide analogue (NA) treatment for 72 wee...

• Country None
• organs None
• Specialty None

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis Badanie służące ocenie leku Toreforant (JNJ-38518168) w leczeniu pacjentów z umiarkowaną do ciężkiej łuszczycą plackowatą” To evaluate the efficacy of JNJ-38518168 in subjects with moderate to severe plaque-type psoriasis. To assess the safety and tolerability of JNJ-38518168 in subjects with moderate to severe plaque-ty...

• Country None
• organs None
• Specialty None

A Phase IIb, multi-centre, randomised, double-blind, active-controlled, trial comparing the neuropsychiatric adverse event profile of etravirine 400 mg q.d. versus efavirenz 600 mg q.d. in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral therapy-naïve HIV-1 infected subjects To compare the proportion of subjects with at least one treatment-emergent Grade 1-4 CNS or psychiatric adverse event, observed between Baseline through Week 12 and judged by the investigator to be at...

• Country None
• organs None
• Specialty None

Étude AQUILA : étude de phase 3 randomisée comparant l’efficacité du daratumumab avec celle d’un suivi actif chez des patients ayant un myélome multiple indolent. [essai clos aux inclusions] Le myélome multiple est une maladie de la moelle osseuse caractérisée par la multiplication dans la moelle osseuse d’un plasmocyte anormal. Le rôle des plasmocytes est de produire les anticorps (immun...

• Country France
• organs Myélomes
• Specialty Immunothérapie - Vaccinothérapie